-$0.35 EPS Expected for Arbutus Biopharma Corp (ABUS) This Quarter

Equities analysts predict that Arbutus Biopharma Corp (NASDAQ:ABUS) will announce earnings per share (EPS) of ($0.35) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Arbutus Biopharma’s earnings, with estimates ranging from ($0.36) to ($0.34). Arbutus Biopharma reported earnings of ($0.44) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 20.5%. The firm is scheduled to issue its next quarterly earnings report on Thursday, August 1st.

On average, analysts expect that Arbutus Biopharma will report full year earnings of ($1.32) per share for the current financial year, with EPS estimates ranging from ($1.78) to ($0.65). For the next fiscal year, analysts anticipate that the firm will report earnings of ($1.09) per share, with EPS estimates ranging from ($1.57) to ($0.53). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Arbutus Biopharma.

Arbutus Biopharma (NASDAQ:ABUS) last released its quarterly earnings data on Monday, May 6th. The biopharmaceutical company reported ($0.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.16). The firm had revenue of $0.70 million for the quarter, compared to analyst estimates of $1.18 million. Arbutus Biopharma had a negative return on equity of 95.26% and a negative net margin of 1,237.92%.

A number of analysts recently weighed in on the stock. Zacks Investment Research cut shares of Arbutus Biopharma from a “buy” rating to a “hold” rating in a report on Friday, January 18th. BidaskClub raised shares of Arbutus Biopharma from a “hold” rating to a “buy” rating in a research note on Tuesday, March 5th. ValuEngine lowered shares of Arbutus Biopharma from a “hold” rating to a “sell” rating in a research note on Wednesday, May 1st. Chardan Capital reaffirmed a “buy” rating and issued a $6.50 price objective on shares of Arbutus Biopharma in a research note on Sunday, March 10th. Finally, Echelon Wealth Partners reaffirmed a “hold” rating on shares of Arbutus Biopharma in a research note on Monday, March 11th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and three have issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $6.25.

A number of institutional investors have recently bought and sold shares of ABUS. BNP Paribas Arbitrage SA bought a new position in Arbutus Biopharma in the 1st quarter worth $26,000. Jefferies Group LLC bought a new position in shares of Arbutus Biopharma during the 1st quarter worth about $36,000. Jacobs Levy Equity Management Inc. bought a new position in shares of Arbutus Biopharma during the 1st quarter worth about $78,000. Legal & General Group Plc increased its holdings in shares of Arbutus Biopharma by 367.7% during the 3rd quarter. Legal & General Group Plc now owns 24,540 shares of the biopharmaceutical company’s stock worth $232,000 after purchasing an additional 19,293 shares during the period. Finally, The Manufacturers Life Insurance Company boosted its position in shares of Arbutus Biopharma by 140.4% during the 1st quarter. The Manufacturers Life Insurance Company now owns 26,188 shares of the biopharmaceutical company’s stock valued at $93,000 after acquiring an additional 15,296 shares in the last quarter. 43.96% of the stock is owned by hedge funds and other institutional investors.

Shares of ABUS stock traded down $0.06 on Friday, reaching $2.40. 127,791 shares of the stock were exchanged, compared to its average volume of 259,025. The company has a market cap of $135.30 million, a price-to-earnings ratio of -2.35 and a beta of 1.61. The company has a quick ratio of 12.75, a current ratio of 12.75 and a debt-to-equity ratio of 0.06. Arbutus Biopharma has a 1-year low of $2.18 and a 1-year high of $12.60.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in Canada and the United States. Its HBV product pipeline consists of AB-506, a capsid inhibitor that has shown improved potency and pharmacokinetics over its first generation capsid inhibitor; and AB-423, which is in pre-clinical studies.

Featured Story: Terms to Better Understand Call Options

Get a free copy of the Zacks research report on Arbutus Biopharma (ABUS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Arbutus Biopharma (NASDAQ:ABUS)

Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.